Gradalis, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2003-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.gradalisinc.com
Clinical Trials
15
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
Expanded Access of Vigil in Solid Tumors
- Conditions
- Solid TumorEwing SarcomaEwing's Tumor MetastaticEwing's Sarcoma MetastaticAdvanced Gynecological CancersOvarian CancerCervical CancerUterine Cancer
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Gradalis, Inc.
- Registration Number
- NCT03842865
- Locations
- 🇺🇸
Texas Oncology - Pediatrics, Dallas, Texas, United States
A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide
- Conditions
- Neoplasms, Connective TissueSarcoma, EwingEwing SarcomaEwing Family of TumorsEwing's Tumor MetastaticEwing's Sarcoma MetastaticEwing's Tumor RecurrentNeoplasms, Bone TissueRare DiseasesSarcoma
- Interventions
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2023-04-26
- Lead Sponsor
- Gradalis, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03495921
- Locations
- 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Southern California Permanente Medical Group, Los Angeles, California, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
- Conditions
- Uterine CancerOvarian CancerAdvanced Gynecological CancersCervical Cancer
- Interventions
- Biological: Vigil
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Gradalis, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT03073525
- Locations
- 🇺🇸
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma
- Conditions
- Ewing's SarcomaEwing's Tumor MetastaticEwing's Tumor RecurrentEwing's Sarcoma MetastaticRare DiseasesEwing Family of TumorsSarcoma
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Gradalis, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT02736565
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Mary Crowley Cancer Research Centers, Dallas, Texas, United States
Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer
- Conditions
- Metastatic Non-small Cell Lung CancerAdvanced Non-small Cell Lung CancerLung Neoplasms
- Interventions
- Biological: Vigil™
- First Posted Date
- 2015-12-24
- Last Posted Date
- 2017-07-31
- Lead Sponsor
- Gradalis, Inc.
- Registration Number
- NCT02639234
- Locations
- 🇺🇸
Texas Oncology, P.A., Texas Cancer Center, Abilene, Texas, United States
🇺🇸Mary Crowley Cancer Research Centers, Dallas, Texas, United States
🇺🇸Cancer Care Northwest, Spokane Valley, Washington, United States
- Prev
- 1
- 2
- 3
- Next